Immunovaccine Announces Dosing of First Patient in Phase 1b Clinical Trial for DPX-Survivac in Combination With Incyte’s IDO1 Enzyme Inhibitor Epacadostat
HALIFAX, NOVA SCOTIA–(Marketwired – Sept. 8, 2016) – Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX:IMV)(OTCQX:IMMVF), a clinical stage [...]